Spyglass Pharma, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
Sands Capital entities and Frank M. Sands have reported significant beneficial ownership in SpyGlass Pharma, Inc., with Frank M. Sands holding 7.8% of common stock.